Zobrazeno 1 - 8
of 8
pro vyhledávání: '"S V, Kulemzin"'
Autor:
V. P. Baklaushev, S. V. Kulemzin, А. А. Gorchakov, V. N. Lesnyak, G. M. Yusubalieva, A. G. Sotnikova
Publikováno v:
Клиническая практика, Vol 11, Iss 1, Pp 7-20 (2020)
COVID-19 (Coronavirus disease 2019) is a new epidemic infectious disease characterized by a relatively high contagiousness and a high probability of life-threatening complications such as acute respiratory distress syndrome (ARDS), acute respiratory
Externí odkaz:
https://doaj.org/article/e076c343b9ec4f65a5c077c800e00f1a
Autor:
V. G. Subrakova, S. V. Kulemzin, T. N. Belovezhets, A. N. Chikaev, N. A. Chikaev, O. A. Koval, A. A. Gorchakov, A. V. Taranin
Publikováno v:
Вавиловский журнал генетики и селекции, Vol 24, Iss 1, Pp 80-86 (2020)
In Russia, cancer is the second leading cause of death following cardiovascular diseases. Adoptive transfer of NK cells is a promising approach to fight cancer; however, for their successful use in cancer treatment, it is necessary to ensure their ro
Externí odkaz:
https://doaj.org/article/00ec533aee1649809b97f8a9cd4bceba
Autor:
G. M. Yusubalieva, E. B. Dashinimaev, A. A. Gorchakov, S. V. Kulemzin, O. A. Brovkina, A. A. Kalinkin, A. G. Vinokurov, M. V. Shirmanova, A. V. Taranin, V. P. Baklaushev
Publikováno v:
Molecular Biology. 56:770-779
Autor:
O. A. Koval, O. Y. Volkova, A. A. Gorchakov, S. V. Kulemzin, A. V. Tkachenko, A. A. Nushtaeva, E. V. Kuligina, V. A. Richter, A. V. Taranin
Publikováno v:
Вавиловский журнал генетики и селекции, Vol 21, Iss 7, Pp 764-769 (2017)
Despite the multitude of anticancer cytostatic drugs available to oncologists today, most of such drugs have serious side effects that may preclude their use in some groups of patients. Hence, selective induction of apoptosis in cancer but not normal
Externí odkaz:
https://doaj.org/article/3ceee83571df4a258286e670dbc8a57b
Publikováno v:
Russian Journal for Personalized Medicine. 2:56-62
In vitro and in vivo experiments often require construction of convenient cell instruments to reliably assess the specificity of the molecules or therapeutic approaches being tested against the protein target of interest. Using model isogenic cell li
Autor:
G M, Yusubalieva, E B, Dashinimaev, A A, Gorchakov, S V, Kulemzin, O A, Brovkina, A A, Kalinkin, A G, Vinokurov, M V, Shirmanova, V P, Baklaushev
Publikováno v:
Molekuliarnaia biologiia. 56(5)
In an experimental study using the CRISPR/Cas9 system, "enhanced" NK cell lines with knockout of CISH, the gene for the CIS protein (a negative regulator of NK cytotoxicity), as well as two lines with a knocked-out β2-microglobulin gene, which provi
Publikováno v:
Acta Naturae
Chimeric antigen receptors (CARs) are recombinant protein molecules that redirect cytotoxic lymphocytes toward malignant and other target cells. The high feasibility of manufacturing CAR-modified lymphocytes for the therapy of cancer has spurred the
Publikováno v:
Molekuliarnaia biologiia. 51(2)
Early results from clinical trials of autologous chimeric antigen receptor (CAR)-expressing T cells for the therapy of B-cell malignancies have encouraged extending the potency of this therapy to other cancers. However, the success of using CAR T-cel